CompletedNCT03454126Updated May 16, 2019

Evaluating the Safety, Tolerability, and Pharmacokinetics of BIIB095 in Healthy Participants

A Phase 1 interventional study of BIIB095 and Placebo in Healthy Volunteer, sponsored by Biogen. Completed at 2 sites in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-05-16.

Sponsored by Biogen · Phase 1, Interventional, and Treatment

Phase: Phase 1
Study type: Interventional
Enrollment: 80
Allocation: Randomized
Ages: 18 Years to 65 Years
Sex: All

Study summary

The primary objective of the study is to evaluate the safety and tolerability of single- and multiple-ascending oral doses of BIIB095 in healthy participants. The secondary objectives are to characterize the single- and multiple-oral-dose PK of BIIB095 in healthy participants and to investigate the effect of food on the single-oral-dose PK of BIIB095 in healthy participants.

Conditions studied

Healthy Volunteer

Keywords

Chronic pain
Neuropathic pain
Neuralgia
Healthy volunteers

Who can participate

Ages eligible: 18 Years to 65 Years
Sexes eligible: All
Accepts healthy volunteers: Yes

Eligibility criteria

Key Inclusion Criteria:

Ability of the subject to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use confidential health information in accordance with national and local subject privacy regulations.
Must have a body mass index between 18 and 30 kg/m2, inclusive.
All women of childbearing potential and all men must practice highly effective contraception during the study and for 5 times the half-life or 3 months, whichever is longer, after their last dose of study treatment. In addition, subjects should not donate sperm or eggs during the study and for at least 3 months after their last dose of study treatment.
Must be in good health as determined by the Investigator, based on medical history and Screening evaluations.

Key Exclusion Criteria:

History of any clinically significant cardiac, endocrine, gastrointestinal, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, or renal disease, or other major disease, as determined by the Investigator.
Significant history of fainting or vaso-vagal attacks, as determined by the Investigator.
Current condition known to affect cardiac conduction, or a personal or familial history of Brugada syndrome.
Congenital nonhemolytic hyperbilirubinemia (Gilbert's syndrome).
History or risk of seizures or a history of epilepsy, significant head injury or related neurological disorders (excluding childhood febrile convulsions), as determined by the Investigator.
Current enrollment in any other drug, biologic, device, or clinical study, or treatment with an investigational drug or approved therapy for investigational use within 30 days (6 months for biologics) prior to Day -1, or 5 half-lives of the agent, whichever is longer.
Exposure to more than 4 experimental chemical entities within 12 months prior to the first dosing day.
Breastfeeding, pregnant, or planning to become pregnant during study participation

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Study design

Phase: Phase 1
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel assignment
Masking: Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment: 80 participants (actual)

Study arms

Experimental
Cohort 1: BIIB095 5 mg
Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 5 mg or placebo orally, followed by a fast of at least 4 hours post dose.
Drug: BIIB095 · Drug: Placebo
Experimental
Cohort 2: BIIB095 25 mg
Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 25 mg or placebo orally, followed by a fast of at least 4 hours post dose.
Drug: BIIB095 · Drug: Placebo
Experimental
Cohort 3: BIIB095 100 mg
Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 100 mg or placebo orally, followed by a fast of at least 4 hours post dose.
Drug: BIIB095 · Drug: Placebo
Experimental
Cohort 4 (Fasted): BIIB095 200 mg
Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 200 mg or placebo orally, followed by a fast of at least 4 hours post dose.
Drug: BIIB095 · Drug: Placebo
Experimental
Cohort 4 (Fed): BIIB095 200 mg
After a minimum 2 week washout period, followed by an overnight fast of at least 8 hours, participants will consume a high fat breakfast. Participants will then receive a single dose of either BIIB095 200 mg or placebo orally within 30 minutes after starting the breakfast, followed by a fast from food for at least 4 hours post dose.
Drug: BIIB095 · Drug: Placebo
Experimental
Cohort 5: BIIB095 400 mg
Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 400 mg or placebo orally, followed by a fast of at least 4 hours post dose.
Drug: BIIB095 · Drug: Placebo
Experimental
Cohort 6: BIIB095 600 mg
Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 600 mg or placebo orally, followed by a fast of at least 4 hours post dose.
Drug: BIIB095 · Drug: Placebo
Experimental
Cohort 7: BIIB095 50 mg BID
Participants will receive a single dose of either BIIB095 50 mg or placebo orally BID approximately 12 hours apart from Days 1 to 13, and once in the morning on Day 14. Morning doses will be preceded by an overnight fast from food of at least 8 hours and will be followed by a fast of at least 2 hours post dose. Evening doses will be preceded by a fast from food of at least 2 hours and will be followed by a fast of at least 2 hours post dose.
Drug: BIIB095 · Drug: Placebo
Experimental
Cohort 8: BIIB095 100 mg BID
Participants will receive a single dose of either BIIB095 100 mg or placebo orally BID approximately 12 hours apart from Days 1 to 13, and once in the morning on Day 14. Morning doses will be preceded by an overnight fast from food of at least 8 hours and will be followed by a fast of at least 2 hours post dose. Evening doses will be preceded by a fast from food of at least 2 hours and will be followed by a fast of at least 2 hours post dose.
Drug: BIIB095 · Drug: Placebo
Experimental
Cohort 9: BIIB095 200 mg BID
Participants will receive a single dose of either BIIB095 200 mg or placebo orally BID approximately 12 hours apart from Days 1 to 13, and once in the morning on Day 14. Morning doses will be preceded by an overnight fast from food of at least 8 hours and will be followed by a fast of at least 2 hours post dose. Evening doses will be preceded by a fast from food of at least 2 hours and will be followed by a fast of at least 2 hours post dose.
Drug: BIIB095 · Drug: Placebo
Experimental
Cohort 10: BIIB095 300 mg BID
Participants will receive a single dose of either BIIB095 300 mg or placebo orally BID approximately 12 hours apart from Days 1 to 13, and once in the morning on Day 14. Morning doses will be preceded by an overnight fast from food of at least 8 hours and will be followed by a fast of at least 2 hours post dose. Evening doses will be preceded by a fast from food of at least 2 hours and will be followed by a fast of at least 2 hours post dose.
Drug: BIIB095 · Drug: Placebo

Interventions

DrugBIIB095
Administered as specified in the treatment arm.
DrugPlacebo
Administered as specified in the treatment arm.

What researchers measure

Primary outcomes

Percentage of Participants with Serious Adverse Events (SAEs)
An SAE is any untoward medical occurrence that at any dose: Results in death; in the view of the Investigator, places the participant at immediate risk of death (a life threatening event), however, this does not include an event that, had it occurred in a more severe form, might have caused death; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; results in a congenital anomaly/birth defect; is a medically important event
Time frame: Signing of Informed Consent (<=28 Days Prior to Day -1, Check-in) to End of Study (Up to 40 Days for Single-Ascending Dose (SAD) Cohorts 1-3 and 5-6; at Least 59 Days for SAD Cohort 4; Up to 53 Days for Multiple-Ascending Dose (MAD) Cohorts 7-10)
Percentage of Participants with Adverse Events (AEs)
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
Time frame: Signing of Informed Consent (<=28 Days Prior to Day -1, Check-in) to End of Study (Up to 40 Days for Single-Ascending Dose (SAD) Cohorts 1-3 and 5-6; at Least 59 Days for SAD Cohort 4; Up to 53 Days for Multiple-Ascending Dose (MAD) Cohorts 7-10)
Percentage of Participants with Clinically Significant Abnormalities in Clinical Laboratory Assessments
Time frame: Signing of Informed Consent (<=28 Days Prior to Day -1, Check-in) to End of Study (Up to 40 Days for Single-Ascending Dose (SAD) Cohorts 1-3 and 5-6; at Least 59 Days for SAD Cohort 4; Up to 53 Days for Multiple-Ascending Dose (MAD) Cohorts 7-10)
Percentage of Participants with Clinically Significant Abnormalities in Vital Signs
Time frame: Signing of Informed Consent (<=28 Days Prior to Day -1, Check-in) to End of Study (Up to 40 Days for Single-Ascending Dose (SAD) Cohorts 1-3 and 5-6; at Least 59 Days for SAD Cohort 4; Up to 53 Days for Multiple-Ascending Dose (MAD) Cohorts 7-10)
Percentage of Participants with Clinically Significant Abnormalities in 12-Lead Electrocardiogram (ECG) Parameters
Time frame: Signing of Informed Consent (<=28 Days Prior to Day -1, Check-in) to End of Study (Up to 40 Days for Single-Ascending Dose (SAD) Cohorts 1-3 and 5-6; at Least 59 Days for SAD Cohort 4; Up to 53 Days for Multiple-Ascending Dose (MAD) Cohorts 7-10)
Percentage of Participants with Clinically Significant Abnormalities in Physical Examinations
Time frame: Signing of Informed Consent (<=28 Days Prior to Day -1, Check-in) to End of Study (Up to 40 Days for Single-Ascending Dose (SAD) Cohorts 1-3 and 5-6; at Least 59 Days for SAD Cohort 4; Up to 53 Days for Multiple-Ascending Dose (MAD) Cohorts 7-10)

Secondary outcomes

Area Under the Concentration-Time Curve (AUC) from Time Zero to the Time of the Last Measurable Concentration (AUClast)
Pharmacokinetic (PK) parameter calculated to assess the PK of BIIB095 in blood.
Time frame: Multiple Time-points on Days 1 through 4 for Single-Ascending Dose (SAD) Cohorts; Multiple Time-points on Days 1 through 15 for Multiple-Ascending Dose (MAD) Cohorts
AUC from Time Zero Extrapolated to Infinity (AUC∞)
Pharmacokinetic (PK) parameter calculated to assess the PK of BIIB095 in blood.
Time frame: Multiple Time-points on Days 1 through 4 for Single-Ascending Dose (SAD) Cohorts; Multiple Time-points on Days 1 through 15 for Multiple-Ascending Dose (MAD) Cohorts
AUC Within a Dosing Interval (AUCtau)
Pharmacokinetic (PK) parameter calculated to assess the PK of BIIB095 in blood.
Time frame: Multiple Time-points on Days 1 through 4 for Single-Ascending Dose (SAD) Cohorts; Multiple Time-points on Days 1 through 15 for Multiple-Ascending Dose (MAD) Cohorts
Maximum Observed Concentration (Cmax)
Pharmacokinetic (PK) parameter calculated to assess the PK of BIIB095 in blood.
Time frame: Multiple Time-points on Days 1 through 4 for Single-Ascending Dose (SAD) Cohorts; Multiple Time-points on Days 1 through 15 for Multiple-Ascending Dose (MAD) Cohorts
Trough Concentration (Ctrough)
Pharmacokinetic (PK) parameter calculated to assess the PK of BIIB095 in blood.
Time frame: Multiple Time-points on Days 1 through 4 for Single-Ascending Dose (SAD) Cohorts; Multiple Time-points on Days 1 through 15 for Multiple-Ascending Dose (MAD) Cohorts
Time to Cmax (Tmax)
Pharmacokinetic (PK) parameter calculated to assess the PK of BIIB095 in blood.
Time frame: Multiple Time-points on Days 1 through 4 for Single-Ascending Dose (SAD) Cohorts; Multiple Time-points on Days 1 through 15 for Multiple-Ascending Dose (MAD) Cohorts
Terminal Elimination Half-Life (t1/2)
Pharmacokinetic (PK) parameter calculated to assess the PK of BIIB095 in blood.
Time frame: Multiple Time-points on Days 1 through 4 for Single-Ascending Dose (SAD) Cohorts; Multiple Time-points on Days 1 through 15 for Multiple-Ascending Dose (MAD) Cohorts
Apparent Total Body Clearance (CL/F)
Pharmacokinetic (PK) parameter calculated to assess the PK of BIIB095 in blood.
Time frame: Multiple Time-points on Days 1 through 4 for Single-Ascending Dose (SAD) Cohorts; Multiple Time-points on Days 1 through 15 for Multiple-Ascending Dose (MAD) Cohorts
Apparent Volume of Distribution (Vz/F)
Pharmacokinetic (PK) parameter calculated to assess the PK of BIIB095 in blood.
Time frame: Multiple Time-points on Days 1 through 4 for Single-Ascending Dose (SAD) Cohorts; Multiple Time-points on Days 1 through 15 for Multiple-Ascending Dose (MAD) Cohorts
Accumulation Ratio (AR)
Pharmacokinetic (PK) parameter calculated to assess the PK of BIIB095 in blood.
Time frame: Multiple Time-points on Days 1 through 4 for Single-Ascending Dose (SAD) Cohorts; Multiple Time-points on Days 1 through 15 for Multiple-Ascending Dose (MAD) Cohorts
Amount (Aeu) Excreted in Urine
Pharmacokinetic (PK) parameter calculated to assess the PK of BIIB095 in blood.
Time frame: Multiple Time-points on Days 1 through 4 for Single-Ascending Dose (SAD) Cohorts; Multiple Time-points on Days 1 through 15 for Multiple-Ascending Dose (MAD) Cohorts
Percentage (%fe) Excreted in Urine
Pharmacokinetic (PK) parameter calculated to assess the PK of BIIB095 in blood.
Time frame: Multiple Time-points on Days 1 through 4 for Single-Ascending Dose (SAD) Cohorts; Multiple Time-points on Days 1 through 15 for Multiple-Ascending Dose (MAD) Cohorts

Study locations

2 sites

Research Site
Leeds, LS2 9LH, United Kingdom
Hammersmith Medicines Research
London, NW10 7EW, United Kingdom

Registry details

Key details

Study ID: NCT03454126
Lead sponsor: Biogen
Responsible party: Sponsor
First posted: Mar 5, 2018
Start date: Mar 29, 2018
Primary completion: Apr 30, 2019
Completion: Apr 30, 2019
Last update: May 16, 2019

Study contacts

Medical Director

study director · Biogen

Oversight

FDA-regulated drug: No
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Biogen

Start the discussion